Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term observational study of Gene Therapy for Sporadic ALS
jRCT2033230284Active, not recruiting
- Sponsor
- ONODERA GT Pharma
- Start
- Aug 2023
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of AAV.GTX-ADAR2 in amyotrophic lateral sclerosis (ALS), sponsored by ONODERA GT Pharma. Primary endpoints: Long-term tolerability of AAV.GTX-ADAR2, Long-term safety of AAV.GTX-ADAR2 and 1 more. Started Aug 2023; status: active, not recruiting.
02
Drugs
AAV.GTX-ADAR2
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on jRCT2033230284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033230284.